RxDoctor Payments Data

Chandan Saw, DO

Internal Medicine · Mountain View, CANPI 1710925284

Payments from drug & device makers

$4,859in general payments, 2019–2025

Across 257 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$993
  • Mylan Specialty L.p.$164
  • Insmed, Inc.$139
  • Philips North America LLC$122
  • plus $294 from 6 others

What the payments were for

  • Food & beverage$4,82499%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,859 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$361,613
Medicare patients
482
Services billed
2,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter302$242,729
Breo ElliptaFluticasone/Vilanterol151$78,443
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$34,255
Spiriva RespimatTiotropium Bromide17$17,504
Spiriva HandihalerTiotropium Bromide15$16,537
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$7,987
Advair HfaFluticasone Propion/Salmeterol17$6,320
Albuterol Sulfate HfaAlbuterol Sulfate225$5,786
SymbicortBudesonide/Formoterol Fumarate22$5,153
Wixela InhubFluticasone Propion/Salmeterol21$4,591
Arnuity ElliptaFluticasone Furoate14$3,741
Levalbuterol Tartrate HfaLevalbuterol Tartrate17$888
Prednisone64$436
Montelukast Sodium28$180
Azithromycin25$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,904$359,168520 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,243$25,49130 claims
AstraZenecaSymbicort$993$5,15322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →